Skip to content

Study · Animal study (in vivo) · mouse · 2013

2 results

Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.

Ripoll GV, Garona J, Pifano M, Farina HG, Gomez DE, Alonso DF

Breast cancer research and treatment1 Nov 2013Cited by 30 (Europe PMC)

PMID24122393 (opens in a new tab)PMCIDPMC3825504 (opens in a new tab)DOI10.1007/s10549-013-2724-6 (opens in a new tab)PepBankPUB-24122393
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mammary carcinoma, intravenous desmopressin markedly decreased vascularization of growing subcutaneous tumors.

    In plain wordsIn mice with mammary cancer, desmopressin reduced blood vessel formation in growing tumors.

    Peptide
    Desmopressin
    Outcome
    DecreaseTumor vascularization
    Study

    mousen: not reported in source

    F3II mammary carcinoma in syngeneic Balb/c mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    2 μg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    Intravenous administration of the compound (2 μg/kg) markedly decreased vascularization of growing subcutaneous tumors, as well as inhibited the early angiogenic response around intradermal inoculation sites.
    1 context sentence
    Summary · context
    Here, we explored the effects of DDAVP on tumor angiogenesis using the aggressive F3II mammary carcinoma in syngeneic Balb/c mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mammary carcinoma, intravenous desmopressin inhibited the early angiogenic response around intradermal inoculation sites.

    In plain wordsIn mice with mammary cancer, desmopressin reduced early blood vessel formation around tumor inoculation sites.

    Peptide
    Desmopressin
    Outcome
    DecreaseEarly angiogenic response
    Study

    mousen: not reported in source

    F3II mammary carcinoma in syngeneic Balb/c mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    2 μg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    Intravenous administration of the compound (2 μg/kg) markedly decreased vascularization of growing subcutaneous tumors, as well as inhibited the early angiogenic response around intradermal inoculation sites.
    1 context sentence
    Summary · context
    Here, we explored the effects of DDAVP on tumor angiogenesis using the aggressive F3II mammary carcinoma in syngeneic Balb/c mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.